The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ckdpharm.com

Founded Year

1941

Stage

IPO | IPO

Date of IPO

12/6/2013

About Chong Kun Dang Pharmaceutical

Chong Kun Dang Pharmaceutical (KRX: 185750) is a Korean pharmaceutical manufacturer that provides prescription drugs indicated for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; OTC drugs such as Penzal, Prefemine, and Modcol; healthcare supplements; and consumer health products such as insecticides and hairdye.

Chong Kun Dang Pharmaceutical Headquarter Location

8, Chungjeong-ro Seodaemun-gu

Seoul, 03742,

South Korea

+82-2-2194-0300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Chong Kun Dang Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Chong Kun Dang Pharmaceutical is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,750 items

Chong Kun Dang Pharmaceutical Patents

Chong Kun Dang Pharmaceutical has filed 27 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Amines
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/28/2014

5/3/2022

Molecular biology, Biotechnology, Gene delivery, Viral plant pathogens and diseases, Liquid crystals

Grant

Application Date

2/28/2014

Grant Date

5/3/2022

Title

Related Topics

Molecular biology, Biotechnology, Gene delivery, Viral plant pathogens and diseases, Liquid crystals

Status

Grant

Latest Chong Kun Dang Pharmaceutical News

Chong Kun Dang scores nod for natural product-based gastritis drug

Jul 20, 2022

Chong Kun Dang scores nod for natural product-based gastritis drug 바로가기 기자명 Kim Chan-hyuk 닫기 Chong Kun Dang Pharmaceutical said it would tap the 350 billion won ($267.4 million) local gastritis market with its new natural product-based treatment. On Monday, the drugmaker won regulatory approval for G-Tec (ingredient: cinnamon bark dried extract) to treat acute and chronic gastritis. Chong Kun Dang recently obtained approval for G-Tec to treat acute and chronic gastritis. Chong Kun Dang said it applied its new extraction method to cinnamon bark, a medical herb. The company said G-Tec is the first natural product-derived medicine that proved efficacy in gastritis. The company has been searing for drug candidates among various herbal medicines and exploring extraction methods since 2013. Then, it found cinnamon bark’s potential to treat gastritis and started developing it as a treatment. In the preclinical phase, the treatment showed an anti-inflammatory effect and its protective factor enhanced gastric mucus secretion. In a phase 2 study, the company confirmed the drug candidate’s benefit in treating gastritis, compared to placebo, existing chemical drugs, and natural product-based medicines. A phase 3 study began in October 2019, aiming to prove G-Tec’s superiority, not non-inferiority, to conventional drugs. The research team divided 242 patients with acute or chronic gastritis into the G-Tec group and the control group (artemisia herb 95 percent ethanol soft extract). The randomized, double-blind, parallel-design, and multicenter study found that G-Tec had superior efficacy in gastritis compared to conventional therapies. According to the phase 3 study results, the G-Tec group showed a 2.25 times higher improvement rate in gastroscopy, the primary endpoint, compared to the control group. In the secondary endpoints such as gastritis cure rate, edema, redness, and bleeding, the company said the G-Tec group showed much better improvement of symptoms. “Unlike a usual comparative study that proves non-inferiority, our study proved G-Tec’s superiority to existing medicines,” an official at Chong Kun Dang said.

Chong Kun Dang Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Chong Kun Dang Pharmaceutical Rank

  • When was Chong Kun Dang Pharmaceutical founded?

    Chong Kun Dang Pharmaceutical was founded in 1941.

  • Where is Chong Kun Dang Pharmaceutical's headquarters?

    Chong Kun Dang Pharmaceutical's headquarters is located at 8, Chungjeong-ro, Seoul.

  • What is Chong Kun Dang Pharmaceutical's latest funding round?

    Chong Kun Dang Pharmaceutical's latest funding round is IPO.

  • Who are the investors of Chong Kun Dang Pharmaceutical?

    Investors of Chong Kun Dang Pharmaceutical include Chong Kun Dang Holdings.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.